Researchers Identify New Target for Heart Failure

A newly discovered transcription factor axis regulates cardiac metabolism, potentially opening pathways for future heart failure treatments.

Updated on Oct. 23, 2026 in Heart Disease

A glass laboratory beaker on a metal workbench with out-of-focus glassware in the background.
Researchers identified the ZEB1-TEAD1 transcription factor axis as a critical regulator of cardiac metabolic homeostasis, potentially aiding future heart failure treatments. AI Illustration. Upload story photo >

Scientists have identified the ZEB1-TEAD1 transcription factor axis as a critical regulator of cardiac metabolic homeostasis. This mechanism maintains essential energy production in the heart, and its disruption is linked to progressive heart failure.

Why it matters

Metabolic reprogramming is a fundamental driver of heart failure, and understanding this regulatory axis provides a new potential therapeutic target. Researchers have demonstrated that manipulating this pathway can restore cardiac function in laboratory models.

In a study of murine models, researchers observed that ZEB1 expression is reduced in failing cardiomyocytes, while ZEB1 overexpression improved outcomes for pressure overload and doxorubicin-induced heart failure.

The players

ZEB1

This is a transcription factor that plays a crucial role in regulating gene expression related to cellular metabolic homeostasis.

TEAD1

This is a protein that functions as a transcription factor and interacts with ZEB1 to regulate metabolic gene pathways in the heart.

The details

The ZEB1 protein interacts with TEAD1 to activate genes such as PKM1 and ACAA2, which govern glycolysis and fatty acid oxidation. When ZEB1 is deleted, the heart suffers from metabolic dysfunction, but researchers found that acetate supplementation can restore function in these deficient models.

Timeline

  1. October 23, 2026: The research findings were formally published.

The Big Picture

This discovery extends the ongoing metabolic reprogramming research in cardiovascular biology by identifying the specific ZEB1-TEAD1 genetic switch that governs essential cardiac energy pathways. It marks a shift toward targeting metabolic regulation to address the underlying causes of heart failure.

This research is in the preclinical stage, meaning it does not currently change existing medical treatments or daily health routines. It provides a foundational scientific basis that may eventually lead to new drug development for patients with heart failure.

The takeaway

The study underscores how vital metabolic balance is for maintaining long-term heart health. While the results are promising for future treatments, they emphasize that heart function is deeply tied to how individual cells process energy.

Further reading

For additional context on current research in this field, visit our Heart Disease section.

More information

Read the complete scientific research article for full experimental details.